-
1
-
-
0029986131
-
Molecular cloning and functional expression of a new human CC-chemokine receptor gene
-
Samson M., Labbe O., Mollereau C., Vassart G., and Parmentier M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 35 (1996) 3362-3367
-
(1996)
Biochemistry
, vol.35
, pp. 3362-3367
-
-
Samson, M.1
Labbe, O.2
Mollereau, C.3
Vassart, G.4
Parmentier, M.5
-
2
-
-
0030018156
-
CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1
-
Alkhatib G., Combadiere C., Broder C.C., Feng Y., Kennedy P.E., Murphy P.M., et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272 (1996) 1955-1958
-
(1996)
Science
, vol.272
, pp. 1955-1958
-
-
Alkhatib, G.1
Combadiere, C.2
Broder, C.C.3
Feng, Y.4
Kennedy, P.E.5
Murphy, P.M.6
-
3
-
-
0005014748
-
The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates
-
Choe H., Farzan M., Sun Y., Sullivan N., Rollins B., Ponath P.D., et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85 (1996) 1135-1148
-
(1996)
Cell
, vol.85
, pp. 1135-1148
-
-
Choe, H.1
Farzan, M.2
Sun, Y.3
Sullivan, N.4
Rollins, B.5
Ponath, P.D.6
-
4
-
-
0030604727
-
A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors
-
Doranz B.J., Rucker J., Yi Y., Smyth R.J., Samson M., Peiper S.C., et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85 (1996) 1149-1158
-
(1996)
Cell
, vol.85
, pp. 1149-1158
-
-
Doranz, B.J.1
Rucker, J.2
Yi, Y.3
Smyth, R.J.4
Samson, M.5
Peiper, S.C.6
-
5
-
-
15844389650
-
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5
-
Dragic T., Litwin V., Allaway G.P., Martin S.R., Huang Y., Nagashima K.A., et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381 (1996) 667-673
-
(1996)
Nature
, vol.381
, pp. 667-673
-
-
Dragic, T.1
Litwin, V.2
Allaway, G.P.3
Martin, S.R.4
Huang, Y.5
Nagashima, K.A.6
-
7
-
-
0036464697
-
Pathways for internalization and recycling of the chemokine receptor CCR5
-
Mueller A., Kelly E., and Strange P.G. Pathways for internalization and recycling of the chemokine receptor CCR5. Blood 99 (2002) 785-791
-
(2002)
Blood
, vol.99
, pp. 785-791
-
-
Mueller, A.1
Kelly, E.2
Strange, P.G.3
-
8
-
-
0033567969
-
CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist
-
Blanpain C., Migeotte I., Lee B., Vakili J., Doranz B.J., Govaerts C., et al. CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. Blood 94 (1999) 1899-1905
-
(1999)
Blood
, vol.94
, pp. 1899-1905
-
-
Blanpain, C.1
Migeotte, I.2
Lee, B.3
Vakili, J.4
Doranz, B.J.5
Govaerts, C.6
-
9
-
-
43949153331
-
CC chemokines in allergic inflammation
-
Baggiolini M., and Dahinden C.A. CC chemokines in allergic inflammation. Immunol Today 15 (1994) 127-133
-
(1994)
Immunol Today
, vol.15
, pp. 127-133
-
-
Baggiolini, M.1
Dahinden, C.A.2
-
11
-
-
0036191430
-
Pharmacological characterization of the chemokine receptor, CCR5
-
Mueller A., Mahmoud N.G., Goedecke M.C., McKeating J.A., and Strange P.G. Pharmacological characterization of the chemokine receptor, CCR5. Br J Pharmacol 135 (2002) 1033-1043
-
(2002)
Br J Pharmacol
, vol.135
, pp. 1033-1043
-
-
Mueller, A.1
Mahmoud, N.G.2
Goedecke, M.C.3
McKeating, J.A.4
Strange, P.G.5
-
12
-
-
30744447460
-
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
-
Fatkenheuer G., Pozniak A.L., Johnson M.A., Plettenberg A., Staszewski S., Hoepelman A.I., et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 11 (2005) 1170-1172
-
(2005)
Nat Med
, vol.11
, pp. 1170-1172
-
-
Fatkenheuer, G.1
Pozniak, A.L.2
Johnson, M.A.3
Plettenberg, A.4
Staszewski, S.5
Hoepelman, A.I.6
-
13
-
-
15744391870
-
The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor
-
Watson C., Jenkinson S., Kazmierski W., and Kenakin T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol 67 (2005) 1268-1282
-
(2005)
Mol Pharmacol
, vol.67
, pp. 1268-1282
-
-
Watson, C.1
Jenkinson, S.2
Kazmierski, W.3
Kenakin, T.4
-
14
-
-
27644510382
-
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity
-
Dorr P., Westby M., Dobbs S., Griffin P., Irvine B., Macartney M., et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49 (2005) 4721-4732
-
(2005)
Antimicrob Agents Chemother
, vol.49
, pp. 4721-4732
-
-
Dorr, P.1
Westby, M.2
Dobbs, S.3
Griffin, P.4
Irvine, B.5
Macartney, M.6
-
15
-
-
0037019271
-
Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity
-
Palani A., Shapiro S., Josien H., Bara T., Clader J.W., Greenlee W.J., et al. Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity. J Med Chem 45 (2002) 3143-3160
-
(2002)
J Med Chem
, vol.45
, pp. 3143-3160
-
-
Palani, A.1
Shapiro, S.2
Josien, H.3
Bara, T.4
Clader, J.W.5
Greenlee, W.J.6
-
16
-
-
13044256383
-
A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
-
Baba M., Nishimura O., Kanzaki N., Okamoto M., Sawada H., Iizawa Y., et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 96 (1999) 5698-5703
-
(1999)
Proc Natl Acad Sci USA
, vol.96
, pp. 5698-5703
-
-
Baba, M.1
Nishimura, O.2
Kanzaki, N.3
Okamoto, M.4
Sawada, H.5
Iizawa, Y.6
-
17
-
-
33646453879
-
Site directed mutagenesis studies of CCR5 reveal differences in the interactions between the receptor and various CCR5 antagonists
-
December 16-19, 2005, Washington
-
Dorr P., Todd K., Irvine R., Robas N., Thomas A., Fidock M., et al. Site directed mutagenesis studies of CCR5 reveal differences in the interactions between the receptor and various CCR5 antagonists. Proceedings of the 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. December 16-19, 2005, Washington (2005)
-
(2005)
Proceedings of the 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
-
-
Dorr, P.1
Todd, K.2
Irvine, R.3
Robas, N.4
Thomas, A.5
Fidock, M.6
-
18
-
-
71849104860
-
Protein measurement with the folin phenol reagent
-
Lowry O., Rosebrough N., Farr A., and Randall R. Protein measurement with the folin phenol reagent. J Biol Chem 193 (1951) 265-275
-
(1951)
J Biol Chem
, vol.193
, pp. 265-275
-
-
Lowry, O.1
Rosebrough, N.2
Farr, A.3
Randall, R.4
-
19
-
-
28244469774
-
Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human
-
Napier C., Sale H., Mosley M., Rickett G., Dorr P., Mansfield R., et al. Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human. Biochem Pharmacol 71 (2005) 163-172
-
(2005)
Biochem Pharmacol
, vol.71
, pp. 163-172
-
-
Napier, C.1
Sale, H.2
Mosley, M.3
Rickett, G.4
Dorr, P.5
Mansfield, R.6
-
20
-
-
40549091358
-
In vitro evaluation of prolonged CCR5 occupancy by small molecule antagonists with anti HIV activity
-
September 14-17, 2003, Chicago
-
Dorr P., Dobbs S., Rickett G., Lewis B., Macartney M., Westby M., et al. In vitro evaluation of prolonged CCR5 occupancy by small molecule antagonists with anti HIV activity. Proceedings of the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. September 14-17, 2003, Chicago (2003)
-
(2003)
Proceedings of the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
-
-
Dorr, P.1
Dobbs, S.2
Rickett, G.3
Lewis, B.4
Macartney, M.5
Westby, M.6
-
21
-
-
0031465316
-
Inverse agonism and the regulation of receptor number
-
Milligan G., and Bond R.A. Inverse agonism and the regulation of receptor number. Trends Pharmacol Sci 18 (1997) 468-474
-
(1997)
Trends Pharmacol Sci
, vol.18
, pp. 468-474
-
-
Milligan, G.1
Bond, R.A.2
-
22
-
-
1642495639
-
Efficacy as a vector: the relative prevalence and paucity of inverse agonism
-
Kenakin T. Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol Pharmacol 65 (2004) 2-11
-
(2004)
Mol Pharmacol
, vol.65
, pp. 2-11
-
-
Kenakin, T.1
-
23
-
-
0042896003
-
UK-427,857, a novel small molecule HIV entry inhibitor is a specific antagonist of the chemokine receptor CCR5
-
February 10-14, 2003, Boston
-
Dorr P., Macartney M., Rickett G., Smith-Burchnell C., Dobbs S., Mori J., et al. UK-427,857, a novel small molecule HIV entry inhibitor is a specific antagonist of the chemokine receptor CCR5. Proceedings of the 10th Conference on Retroviruses and Opportunistic Infections. February 10-14, 2003, Boston (2003)
-
(2003)
Proceedings of the 10th Conference on Retroviruses and Opportunistic Infections
-
-
Dorr, P.1
Macartney, M.2
Rickett, G.3
Smith-Burchnell, C.4
Dobbs, S.5
Mori, J.6
-
24
-
-
32944470681
-
The development of an europium-GTP assay to quantitate chemokine antagonist interactions for CXCR4 and CCR5
-
Labrecque J., Anastassov V., Lau G., Darkes M., Mosi R., and Fricker S.P. The development of an europium-GTP assay to quantitate chemokine antagonist interactions for CXCR4 and CCR5. Assay Drug Dev Technol 3 (2005) 637-648
-
(2005)
Assay Drug Dev Technol
, vol.3
, pp. 637-648
-
-
Labrecque, J.1
Anastassov, V.2
Lau, G.3
Darkes, M.4
Mosi, R.5
Fricker, S.P.6
-
25
-
-
0035940445
-
SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo
-
Strizki J.M., Xu S., Wagner N.E., Wojcik L., Liu J., Hou Y., et al. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci USA 98 (2001) 12718-12723
-
(2001)
Proc Natl Acad Sci USA
, vol.98
, pp. 12718-12723
-
-
Strizki, J.M.1
Xu, S.2
Wagner, N.E.3
Wojcik, L.4
Liu, J.5
Hou, Y.6
-
26
-
-
27144491979
-
Analysis of allosterism in functional assays
-
Ehlert F.J. Analysis of allosterism in functional assays. J Pharmacol Exp Ther 315 (2005) 740-754
-
(2005)
J Pharmacol Exp Ther
, vol.315
, pp. 740-754
-
-
Ehlert, F.J.1
-
27
-
-
33751183557
-
Determining the potency and molecular mechanism of action of insurmountable antagonists
-
Kenakin T., Jenkinson S., and Watson C. Determining the potency and molecular mechanism of action of insurmountable antagonists. J Pharmacol Exp Ther 319 (2006) 710-723
-
(2006)
J Pharmacol Exp Ther
, vol.319
, pp. 710-723
-
-
Kenakin, T.1
Jenkinson, S.2
Watson, C.3
-
28
-
-
34547714401
-
Antagonism of the CCR5 receptor by SCH-C leads to elevated beta-chemokine levels and receptor expression in chronically treated PBMC cultures
-
February 24-28, 2002, Seattle
-
Xu L., Wojcik N., and Strizki J.M. Antagonism of the CCR5 receptor by SCH-C leads to elevated beta-chemokine levels and receptor expression in chronically treated PBMC cultures. Proceedings of the 9th Conference on Retroviruses and Opportunistic Infections. February 24-28, 2002, Seattle (2002)
-
(2002)
Proceedings of the 9th Conference on Retroviruses and Opportunistic Infections
-
-
Xu, L.1
Wojcik, N.2
Strizki, J.M.3
-
29
-
-
34547705105
-
Pharmacogenetic analysis of polymorphisms in the chemokine receptors CCR5 and CCR2 in the clinical development of a CCR5 antagonist (UK-427,857) for the treatment of HIV/AIDS
-
February 20, 2004, Washington
-
Penny M., Myrand S., Lin C., Boucher M., Man M., and James I. Pharmacogenetic analysis of polymorphisms in the chemokine receptors CCR5 and CCR2 in the clinical development of a CCR5 antagonist (UK-427,857) for the treatment of HIV/AIDS. FDA Science Symposium. February 20, 2004, Washington (2004)
-
(2004)
FDA Science Symposium
-
-
Penny, M.1
Myrand, S.2
Lin, C.3
Boucher, M.4
Man, M.5
James, I.6
|